Imatinib Pharmacokinetics and Its Correlation With Response and Safety in Chronic-Phase Chronic Myeloid Leukemia: A Subanalysis of the IRIS Study

Blood - United States
doi 10.1182/blood-2007-10-116475
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology

Related search

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Polycomb Genes Are Associated With Response to Imatinib in Chronic Myeloid Leukemia

Epigenomics
Cancer ResearchGenetics
2015English

Long-Term Safety and Efficacy of Dasatinib in the Treatment of Chronic-Phase Chronic Myeloid Leukemia Patients Resistant or Intolerant to Imatinib

Blood and Lymphatic Cancer: Targets and Therapy
2014English

Influence of CYP3A5 and Drug Transporter Polymorphisms on Imatinib Trough Concentration and Clinical Response Among Patients With Chronic Phase Chronic Myeloid Leukemia

Journal of Human Genetics
Genetics
2010English

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Reduced-Intensity Allogeneic Transplantation Combined With Imatinib Mesylate for Chronic Myeloid Leukemia in First Chronic Phase

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Failure of a Non-Authorized Copy Product to Maintain Response Achieved With Imatinib in a Patient With Chronic Phase Chronic Myeloid Leukemia: A Case Report

Journal of Medical Case Reports
Medicine
2009English

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy